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Summary Antibodies against Candida albicans antigenic determinants have been reported to cross-react with human tumour cells. We have
found that two monoclonal antibodies, C6 and PAlOF, developed at our laboratory against C. albicansantigenic determinants, cross-react with
human ovarian cancer on Western blots and immunohistochemistry. We have subsequently used one of them, PA1OF, to test by means of
immunohistochemistry a series of 37 human ovarian carcinomas. Out of 37 tumours, 25 (67.6%) expressed the antigen recognized by PAlOF.
The reactivity, however, was concentrated on the subgroup of particularly aggressive, invasive carcinomas in advanced stages of the disease
(19 out of 24 positive), whereas the antigen was expressed significantly less (P = 0.0007) in the subgroup of much less aggressive stage I
tumours of low malignant potential, also called borderline carcinomas (2 out of 13 positive). This cross-reactivity between C. albicans and
ovarian carcinoma seems to be attributable to a common antigenic determinant related to tumour aggressiveness.
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It has been described recently by Yasumoto et al (1993) that anti-
bodies against Candida albicans antigenic determinants may
also react with human tumour cells. These authors have reported
that a mouse monoclonal antibody developed against Candida
cytochrome c specifically reacts with the cytoplasmic fraction of
human lung cancer cells. Previously, this same research group had
shown that, conversely, cytochrome c from Candida krusei speci-
fically reacted with sera from patients harbouring lung tumours,
whereas horse and bovine cytochrome c did not, suggesting a
unique cross-reactivity between yeast and human tumour cells'
antigenic determinants, which could serve eventually for diag-
nostic purposes (Hashizume at al, 1991).
On the other hand, heat shock proteins (HSP) have emerged
recently as important links in the chain leading to the development
ofthe malignant phenotype (Lindquist and Craig, 1988). These are
among the most conserved proteins throughout evolution and,
although first identified, as theirname suggests, in response to heat
shock, it has now been recognized that they are induced by many
kinds ofcellular stress, such as oxidative injury, exposure to heavy
metals, serum deprivation, etc., and that some of them play a
defined role in cancer. In tumour cells, HSPs have been shown to
act as tumour antigens, to be involved in proliferation and
apoptosis, to interact with oncogenes and p53 and, finally, to play
a role in thermotolerance and the development of drug resistance
by tumour cells (Fuller et al, 1994).
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Our group has been working during the past few years on the
development of monoclonal antibodies against C. albicans anti-
genic determinants, also including C. albicans heat shock manno-
proteins (Ponton et al, 1993; Polonelli et al, 1994). We have tested
a panel of these antibodies on human ovarian carcinoma tissue,
and two of them showed promising initial results in a small
preliminary study. One of them was subsequently used to test a
series of very aggressive ovarian cancers compared with a control
group of borderline ovarian carcinoma tumours by means of
immunohistochemistry. The scope of this pilot study was, firstly,
to investigate whether these antibodies can be used for immuno-
histochemistry on human tumour tissues at all; secondly, to inves-
tigate whether they do react specifically with tumour cells and
whether the reaction is confined to tumour tissue alone or involves
other (normal) cells; and, finally, to determine the pattem of
reactivity (cytoplasmic, nuclear or both).
MATERIALS AND METHODS
Monoclonal antibodies
Two monoclonal IgM antibodies (PAlOF and C6) were used. They
were produced following standard methods in BALB/c mice
immunized by subcutaneous injections of a partly purified antigen
of 260 kDa from germ tubes (PAlOF) and a partly purified heat
shock mannoprotein of 200 kDa from a blastoconidium extract
(C6) as previously described (Ponton et al, 1993; Polonelli et al,
1994). Antibodies used in this study were contained in ascites fluid
from mice injected with the hybridomas. In one experiment, a
monoclonal antibody against C. albicans enolase (ATCC no. HB
8397), a monoclonal antibody against neuron-specific enolase
(NSE-BBS, Dako, Denmark), a monoclonal antibody against HSP
27 (Novocastra, Newcastle, UK) and a monoclonal antibody
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against HSP 60 (Lk2, Sigma Chemical, St Louis, MO, USA) were
also used.
Tissue extraction
Fresh tumourbiopsies fromhuman ovarian carcinomas and normal
ovarian tissue were suspended in 10 mM Tris-HCl buffer, pH 6.8,
and homogenized with a Potter-Elvejheim homogenizer at 4°C.
The extracts were centrifuged at 13 000 r.p.m. for 5 min at 4°C.
Candida albicans
Candida albicans serotype A (NCPF 3153) was obtained from the
National Collection of Pathogenic Fungi (Bristol). It was main-
tained at 4°C on slants containing 20 g of glucose, 10 g of yeast
extract and 20 g of agar per litre. Candida albicans was grown in
medium 199 (Sigma) at 24°C and 37'C as previously described
(Ponton and Jones, 1986) The fungal cell walls were extracted for
4 h in the presence of dithiothreitol (DTT) as described by Smail
and Jones (1984).
SDS-PAGE and Western blotting
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed in a minigel system (Bio-Rad
Laboratories, Richmond, CA, USA). The total amount of protein
loaded per lane was 10 jg for each tissue extract and 5 ig for each
C. albicans extract. Electrophoresis was carried out in 10% (w/v)
acrylamide at 200 V for 40 min. Standard molecular weight
markers were from Bio-Rad. Subsequently, the gels were either
stained with Coomassie blue or were electrophoretically trans-
ferred to a nitrocellulose membrane (Bio-Rad) for 30 min at 60 V,
10 W and 5 mA cm-2 using the Fast Blot System (Biometra,
Germany). After the transfer, the nitrocellulose membranes were
blocked in 8% (w/v) non-fat dry milk in Tris-buffered saline
(TBS), washed in TBS and incubated with the monoclonal anti-
bodies (PAlOF diluted 1:8 in TBS, C6 diluted 1:50 in TBS, HB
8397 diluted 1:6 in TBS and NSE-BBS diluted 1:40 in TBS),
A
Figure 1 Western blots of 10% polyacrylamide gels loaded with normal
human ovarian tissue (lane 1) and ovarian tumour extracts (lanes 2-4),
stained with monoclonal antibodies PAl OF (A) and C6 (B). Molecular
masses of standard proteins are listed on the left of the gel
washed and incubated with peroxidase-labelled, affinity-purified
goat anti-mouse IgM or IgG (Sigma). Immunoreactive bands were
visualized after staining for 30 min with a substrate solution
[0.05% (w/v) 4-chloro-1-naphthol (Sigma) and 0.015% (v/v)
hydrogen peroxide in TBS]. In some experiments, the antigens
present on the nitrocellulose membrane were treated with 50 mM
sodium periodate as described by Sundstrom and Kenny (1984)
and incubated with MAb C6 as described above.
Immunohistochemistry
The immunohistochemical procedure was carried out on 5-gm
sections from routinely processed, formalin-fixed, paraffin-
embedded tumourblocks. The technique itselfwas a variant ofthe
usual streptavidin-biotin-peroxidase method previously described
by us for fresh-frozen tissue (Schneider et al, 1994) and also
for paraffin-embedded samples (Schneider and Romero, 1995).
To ensure uniformity of results, we used a commercial
streptavidin-biotin-peroxidase kit (Histostain-SP, Zymed, San
Francisco, CA, USA) throughout the whole procedure, which was
carried out entirely at room temperature. As positive controls, we
used slides from mammary carcinomas known to express high
levels of HSP60 and HSP27. The monoclonal antibodies used
were PAlOF, C6, NCL-HSP27 and Lk2 HSP60.
Briefly, the slides were deparaffinized in three xylene baths,
5 min each, and then rehydrated in phosphate-buffered saline (PBS)
for 10 min after passages through graded ethanols (100%, 96%,
70%), 3 mineach. Afterwards, thepreparations were incubatedwith
blocking serum (component 1A of the kit) for 10 min and subse-
quently with the monoclonal antibody (PAlOF mouse ascites fluid
diluted 1:100, C6 mouse ascites fluid diluted 1:1000, NCL-HSP27
diluted 1:20 and Lk2 HSP60 diluted 1:100) for 1 h in a humid
chamber. They werethen washed inPBS threetimes for 3 min, after
whichthe second, biotinylatedbridge antibody was applied (compo-
nent lB of the kit) for 10 min. After three washes in PBS, 3 min
each, the slides were incubated with the streptavidin-peroxidase
complex (component IC ofthe kit) for 10 min, washed again three
times in PBS and stained with amino-ethyl-carbazole for 3 min.
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Figure 2 Western blots of 10% polyacrylamide gels loaded with cell wall
extracts from C. albicans cells grown at 25 (lanes 1 and 3) and 370C (lanes 2
and 4), stained with monoclonal antibodies PAl OF (lanes 1 and 2) and C6
(lanes 3 and 4). Molecular masses of standard proteins are listed on the left
of the gel
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They were then counterstained with haematoxylin for 30 s and
mounted with aqueous mounting medium. Slides from each tumour
were processed in parallel in identical fashion, but omitting the
monoclonal antibody and leaving them with the blocking serum
instead, and served as negative controls. In the case of the tumours
exposed to the PAlOF antibody, an additional negative control was
introduced by incubating slides with ascites fluid obtained from
mice injected with the same (unfused) myeloma cells used for the
production of the monoclonal antibody, at the same dilution as
the ascites fluid containing the antibody, to exclude any kind of
unspecific reaction.
For the evaluation of the results of this study, we adopted the
semiquantitative scale used previously by us (Schneider et al,
1994), which takes into account both the strength of the staining
reaction as well as the proportion ofreactive tumour cells. Hence,
+ stands for staining of lower intensity than the positive control
and ++ for staining of equal or higher intensity than the positive
control. Isolated tumour cells or tumour cell groups, comprising
less than 5% of visible tumour cells were termed 'a', with 'b'
designating up to 20% reactive tumour cells and 'c' very numerous
(20-100%) reactive cells.
Table 1 Preliminary evaluation of immunohistochemical reactivity of MAb
PAlOF and MAb C6 with human ovarian carcinoma
Tumour Aggressiveness C6 PAlOF
specimen
1 Invasive + +
2 Invasive + +
3 Invasive +
4 Invasive + +
5 Invasive + +
6 Invasive + +
7 Invasive + +
8 Invasive +
9 Invasive +
10 Invasive + +
11 Borderline +
12 Borderline +
13 Borderline + +
14 Borderline +
MAb PA10F diluted 1:100; MAb C6 diluted 1:1000.
A
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Figure 3 Immunohistochemical staining of ovarian carcinomas. Streptavidin-biotin-peroxidase method. (A) PAlOF monoclonal antibody. Intense,
homogeneous cytoplasmic staining in all tumour cells, as opposed to surrounding normal tissue. (B) Negative control of A, incubated with murine ascites fluid
elicited by injection of the same myeloma cells used for the production of PAlOF. (C) HSP60 expression in ovarian carcinoma; intense granular cytoplasmic
staining pattern. (D) HSP27 expression in ovarian carcinoma; homogeneous cytoplasmic staining in tumour cell clusters
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Statistics
To evaluate the association between qualitative variables, we used
the chi-square test with the continuity correction of Yates. Values
were considered significant when P was <0.05.
RESULTS
Monoclonal antibody PAlOF reacted with a band of 74 kDa that
was only present on the extracts from the ovarian carcinomas. A
non-specific band of 83 kDa was present in all the ovarian speci-
mens studied, although the intensity of staining varied among
them. This band corresponded to the reactivity of the second
bridge antibody with ovarian antigens, as it was also present in the
negative controls incubated omitting the monoclonal antibody.
Monoclonal antibody C6 reacted with a band of 43 kDa specifi-
cally expressed on the ovarian carcinomas (Figure 1).
The reactivity of both monoclonal antibodies with C. albicans
antigens was studied at two temperatures. Monoclonal antibody
PAlOF stained a component of 48 kDa, which was present in
extracts from cells grown at 24°C and 37°C (Figure 2).
Monoclonal antibody C6 reacted with the same antigenic compo-
nent of 48 kDa and with a variety of high-molecular-weight
components, which seemed to be expressed more in extracts from
cells grown at 37°C than in extracts from cells grown at 25°C.
We performed a preliminary study on a randomly chosen subset
of ten invasive and four borderline ovarian carcinomas to define
the optimal dilution of each monoclonal antibody for immunohis-
tochemistry. The results are summarized in Table 1. Monoclonal
antibody C6 reacted uniformly with all tumour specimens.
Conversely, monoclonal antibody PA1OF reacted only with some
tumour specimens and seemed to discriminate between more and
less aggressive variants (Table 1).
Subsequently, 37 human ovarian carcinomas were studied for
the expression of the antigen recognized by PAIOF, initially devel-
oped against C. albicans antigenic determinants. Furthermore,
those same samples were also studied for the overexpression of
HSP60 and HSP27. Twenty-five out of 37 tumours (67.6%)
expressed the antigen recognized by PAlOF. High levels of expres-
sion (more than 20% of tumour cells) were registered among 19
out of 24 aggressive, advanced-stage tumours and only 2 out of 13
of the much less aggressive, early-stage borderline ovarian carci-
nomas. This difference in expression was statistically significant
(P = 0.0007) and seems to indicate that the PA1OF antigen is in
some way related to the malignancy ofthe tumours.
Only tumour tissues expressed the antigen, normal tissue
surrounding the tumour nests being negative by immunohisto-
chemistry (Figure 3A). The reaction elicited by the PAIOF anti-
body was cytoplasmic, homogeneous in distribution and visually
different from the one displayed by tumours expressing HSP60 or
HSP27; both these reactions were also located in the cytoplasm of
tumour cells, but the one corresponding to HSP60 expression was
much more coarsely granular, the granules being very intensely
stained (Figure 3C). The reaction seen in HSP27-expressing
tumour cells, on the other hand, was smooth and homogeneous in
distribution, but tended to be centred on intensely stained clusters
of tumour cells (Figure 3D). HSP60 was expressed by 4 out of 37
tumours, whereas HSP27 was expressed by 18 out of 37 tumours.
There was no correlation between the expression of PAlOF with
either HSP60 or HSP27 (Table 2).
Table 2 Immunohistochemical reactivity of MAb PAlOF with human ovarian
carcinoma. Comparison with expression of HSP60 and HSP27.
Streptavidin-biotin-peroxidase
Histology Stage PA1OF HSP60 HSP27
1 Serous IlIl +a - ++a
2 Serous IV ++c
3 Undifferentiated IV ++c - ++a
4 Serous IV
5 Endometrioid III +c - ++b
6 Serous IlIl ++c - ++a
7 Serous IlIl ++c - +a
8 Undifferentiated III ++c -
9 Undifferentiated IlIl ++c ++c
10 Serous IV ++c -
11 Serous IlIl ++c - +a
12 Serous IlIl - - +a
13 Serous III +c -
14 Endometrioid III ++c -
15 Serous III +c - ++c
16 Serous IlIl ++c - +a
17 Serous IlIl ++c ++c ++a
18 Endometrioid IlIl ++c - +c
19 Clear cell III +c - +a
20 Mucinous IlIl
21 Serous III +c - +a
22 Endometrioid IlIl ++c - +a
23 Serous IlIl - - ++b
24 Endometrioid IlIl ++c ++b +a
25 Mucinous
26 Serous
27 Serous - ++b
28 Serous
29 Serous - - +b
30 Serous
31 Mixed
32 Serous +b - -
33 Mucinous +b - -
34 Serous ++c - -
35 Serous ++c - -
36 Serous +b - +b
37 Mucinous
-, No detectable expression; +, expression weaker than positive control;
++, expression equal to or stronger than positive control; a, isolated (< 5%)
positive tumour cells; b, 5-20% positive tumour cells; c, very numerous
(> 20%) positive tumour cells.
In a further effort to characterize the antigen recognized by
monoclonal antibody PA1OF, and taking into consideration that a
protein of48 kDa in C. albicans will mostprobably be an enolase,
the extracts were incubated with a monoclonal antibody specific
for C. albicans enolase. Indeed, the anti-enolase monoclonal anti-
body stained the same band in C. albicans, whereas in human
tissue specimens the bandrecognizedby this antibody was entirely
different fromthe ones recognizedby eitherPAlOF orC6 (data not
shown). As a final step, we incubated the human tissue extracts
with an anti-human neurone-specific enolase monoclonal anti-
body. The band recognized by it was again different to that recog-
nized by monoclonal antibodies PAlOF and C6 (data not shown).
DISCUSSION
Cross-reactivity between C. albicans and ovarian antigenic deter-
minants was first reported by Mathur et al (1980). They deter-
mined antibody titres against C. albicans in the sera from patients
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with chronic vaginal candidiasis and found a significant correla-
tion with autoantibody titres against the ovary and the thymocytes.
Absorption of those same sera with either Candida cells, ovarian
follicle cells or thymocytes reduced all three antibody titres
concomitantly, suggesting a common antigen or at least a high
cross-reactivity between different antigenic determinants. The
authors speculated that these might be similar receptor proteins,
such as the concanavalin A receptor, which is shared by blas-
tospores of C. albicans, T lymphocytes and the ovary. As an alter-
native explanation, they offered the possibility that high levels of
anti-Candida antibodies secreted during active infection might,
because oftheir multispecificity, trigger an active immune reaction
to cross-reacting antigens on ovary and lymphocytes.
Hashizume et al (1991) were the first to report a cross-reactivity
between a monoclonal antibody produced by a human-human
hybridoma originating from a patient with lung large-cell carci-
noma (HB4C5) and a yeast antigenic determinant, notably
cytochrome c from Candida krusei. Shortly thereafter, Yasumoto
et al (1993) developed a mouse monoclonal antibody against C.
krusei cytochrome c (HCC 5), which specifically reacted to the
cytoplasmic fraction of human lung cancer cells. Finally,
Kawamoto et al (1995) have isolated a 21-kDa polypeptide
containing a six-amino-acid sequence (ALLFFT), similar to the
cytochrome c epitope, although the mRNA encoding the whole
protein is apparently different from the cytochrome c mRNA. This
last finding offers an explanation for the cross-reactivity between
yeast and human lung cancer cells' antigenic determinants
observed by the Japanese research group. At the same time, it
seems to indicate that the antigen recognized in tumour cells is not
simply cytochrome c, but possibly a novel tumour antigen.
Our PAIOF and C6 monoclonal antibodies, as with the mono-
clonal antibody described by Yasumoto et al (1993), also react
specifically (and strongly) with the cytoplasm of human ovarian
carcinoma cells. Furthermore, the PAlOF monoclonal antibody
developed by us seems to react with an antigenic determinant that
is possibly related to the proliferation of tumour cells, as the
protein recognized by it is expressed significantly more in the most
aggressive variants of the ovarian cancer studied here (advanced
stage, invasive carcinomas), if compared with a more indolent
form ofovarian tumour, such as borderline carcinomas.
As can be seen from Figures 1 and 2, the bands recognized by
the monoclonal antibodies PAIOF and C6 in Candida and human
tumour tissue are not the same. As shown in the Results section,
the protein recognized by both C6 and PAIOF monoclonal anti-
bodies in C. albicans is enolase, an immunodominant antigen of C.
albicans (Sundstrom and Aliaga, 1994). Concomitantly, the band
reacting with either antibody in human tissue extracts was found
not to be enolase. Considering the results reported by Kawamoto et
al (1995) showing that the cross-reaction observed by them
between C. krusei cytochrome c and human lung cancer cells was
elicited by a common sequence of only six amino acids, it might
well be that we face a similar phenomenon ofcross-reaction due to
a short common amino acid sequence.
As monoclonal antibody C6 was initially raised against Candida
albicans heat shock proteins, we initially hypothesized that one of
these could be shared by yeast and ovarian cancer tumour cells,
and somehow play a role in cell growth and proliferation.
However, unfortunately, it did not show a clean staining reaction
on immunohistochemistry, at least as used on the formalin-fixed,
paraffin-embedded tumour samples in this study. In spite of the
high dilution used, it showed a relatively strong background
component that made evaluation of the slides difficult. This
contrasts with the neat results obtained with this antibody by
Western blotting, which, however, were carried out on fresh-frozen
tissue, so that the unsatisfactory results obtained on immunohisto-
chemistry may be attributable to damage ofthe epitope by the fixa-
tion.
From our initial characterization of the antibody reactions on
Western blots, however, it seems that the protein recognized by
PA1OF is not related to the heat shock proteins commonly involved
in cancer, such as HSP70 and, particularly in ovarian cancer,
HSP60 (Kimura et al, 1993). The same tumour tissues studied by
us using the PAlOF antibody by means of immunohistochemistry
have also been tested for HSP60 expression and, expectedly, have
shown an entirely different pattern of reactivity (Figure 3). The
same was the case for HSP27 positivity. Thus, the cross-reactivity
observed by us between C. albicans and ovarian carcinoma
seems to be attributable to a common antigenic determinant, not
described up to now, playing a role in the oncogenic activation of
ovarian tumour cells. The definitive characterization ofthis protein
will involve the cloning ofthe gene encoding it.
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